Main Article Content
Objective: Zinc is an essential trace element for the body that is involved in various significant body functions such as protein synthesis, DNA synthesis, and cellular growth. It is found in almost every cell and plays an important role in the immune system, affecting both innate and acquired immunity. Patients with beta-thalassemia major are at risk of zinc deficiency. Beta-thalassemia major is an inherited disease caused by a reduction or complete absence of beta-globin chains and the affected patients need repeated blood transfusions to survive. Accordingly, it causes oxidative stress and tissue damage, alteration of antioxidant enzymes, and changes in other essential trace element levels due to iron overload. Zinc levels in beta-thalassemia major patients were reported to be significantly reduced in most of the studies. Serum zinc levels of the patients with beta-thalassemia major should be monitored regularly and zinc supplementation should be provided to these patients.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
2. Hemmens B, Goessler W, Schmidt K, Mayer B. Role of bound zinc in dimer stabilization but not enzyme activity of neuronal nitric-oxide synthase. J Biol Chem. 2000;275:35786–91.
3. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. Nutrients. 2017;9(6):624.
4. Lu J, Stewart AJ, Sadler PJ, Pinheiro TJT, Blindauer CA. Albumin as a zinc carrier: Properties of its high affinity zinc-binding site. Biochem Soc Trans. 2008;36:1317–21.
5. Mocchegiani E, Costarelli L, Giacconi R, Cipriano C, Muti E, Malavolta M. Zinc-binding proteins and immunosenescence. Exp Gerontol. 2006;41:1094–107.
6. Cunningham M. The thalassemias. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, editors. Nathan and Oski's Hematology of Infancy and Childhood, 7th edition. Philadephia: Saunders Elsevier; 2009. p.1015-106.
7. Dehshal MH, Hooghooghi AH, Kebryaeezadeh A, Kheirabadi M, Kazemi S, Nasseh A, et al. Zinc deficiency aggravates abnormal glucose metabolism in thalassemia major patients. Med Sci Monit. 2007;13(5):235-9.
8. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
9. Cunningham MJ, Macklin E, Neufeld EJ, Cohen AR. Complications of B-thalassemia major in North America. Blood. 2004;104:34–9.
10. Weatherall DJ, Clegg JB. Management and prognosis in the thalassemia syn- dromes. 4th ed. Oxford, UK: Blackwell Scientiﬁc; 2001. p:630–85.
11. Ceci A, Mangiarini L, Felisi M, Bartoloni F, Ciancio A, Capra M, et al. The man- agement of iron chelation therapy: preliminary data from a national registry of thalassaemic patients. Anemia. 2011;2011:435683.
12. Mehdizadeh M, Zamani G, Tabatabaee S. Zinc status in patients with major